Bpen 1000

BPEN 1000











In serious Nosocomial and ICU
infections you & your ultimate decision can save lives

Ideal monotherapy in Specticemia,
Pyogenic Meningitis & Ventilator Associated pneumonia

Greater safety & Tolerability

Better CNS tolerability compared to
imipenemSafe in children above 3 monthsBolus administration convenience



Severe Nosocomial RTI
Meropenem 81% vs 72% Ceftazidime +
Amikacin

Meningitis
Meropenem 98% vs 92% Cephalosporins


Indications

MeningitisNosocomial PneumoniaIntra-Abdominal infectionsUrinary tract infectionsSkin & soft tissue infectionsGynaecological infectionsFebrile neutropeniaCystic fibrosis








In serious ICU infections

Excellent clinical response rates (%)
Nosocomial infections

Meropenem: 87%Imipenem/cilastatin: 74%


Community acquired pneumonia
Meropenem: 93%Imipenem/Cilastatin: 79%


Intra-abdominal infectionsMeropenem: 93.5%Imipenem/cilastatin: 76.7%



LRTI

Meropenem: 83%Imipenem/ Cilastatin: 56%